Company patents
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. demonstrates a clear, yet surprising, shift in its patent strategy, with its core "Pharmaceutical Preparations" category, representing 86.8% of its portfolio, showing a consistent decline in new patent filings, including a -38.9% YoY drop in 2025 and a -9.1% decline so far in 2026. This trend is mirrored in "Therapeutic Activity (Pharma)" (55.3% of portfolio), which saw a -47.4% YoY decrease in 2024 and a -37.5% decline so far in 2026, indicating a significant de-emphasis on expanding its primary pharmaceutical IP.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
76 US filings (since 2023) · 9 categories · 11 themes
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development and use of engineered biological systems, such as organ-on-a-chip devices, dynamic hydrogels, or genetically modified cells, to mimic physiological conditions, study disease mechanisms, screen compounds, or develop cell-based therapies.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Patents
Showing 1-10 of 162